Testosterone Replacement Therapy (TRT) Beneficial in Diabetes Mellitus Patients
the Renal and Urology News take:
Testosterone replacement therapy (TRT) may lower hemoglobin levels and improve lipid profile in diabetic men with androgen deficiency, according to a recent study published in the European Journal of Medical Research.
Shota Jangjgava, MD, of the National Institute of Endocrinology and fellow researchers examined a 85 male patients with diabetes mellitus who were treated with either TRT in addition to dietary intervention, physical exercise and anti-diabetes, or placebo with the same interventions, exercise and medication.
They found that, after six months, the lipid profiles in the TRT group were significantly improved. HbA1c levels were also greatly reduced compared to those who were not treated with testosterone.
TRT was found to have no effect on leptin and blood pressure levels. Previous studies have noted a correlation between leptin and its effect on TRT in relation to diabetes mellitus and metabolic syndrome.
“It is possible to break this metabolic vicious circle by raising testosterone levels in diabetic men with androgen deficiency,” the authors concluded.
TRT may lower hemoglobin levels and improve lipid profile in diabetic men with androgen deficiency.
The aim of our study was to show the influence of testosterone replacement therapy on obesity, HbA1c level, hypertension and dyslipidemia in patients with diabetes mellitus and androgen deficiency.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
Renal and Urology News Articles
- Study: Older Age Should Not Preclude Partial Nephrectomy
- Lower Blood Pressure May Protect Against Renal Events in T1DM
- CB-839 Drug Promising for Clear Cell, Papillary Renal Cell Cancer
- Guideline Confirmed for UTI in Children With Fever
- Survival Benefit Linked With Adjuvant RT+ADT in Lymph Node + PCa